A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.

@article{Etgen2002ATT,
  title={A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.},
  author={G. Etgen and B. A. Oldham and W. T. Johnson and C. Broderick and Chahrzad Montrose and J. Brozinick and Elizabeth A Misener and J. Bean and W. Bensch and D. Brooks and A. Shuker and C. J. Rito and J. Mccarthy and R. Ardecky and J. Tyhonas and S. Dana and J. Bilakovics and J. Paterniti and K. Ogilvie and Shan Liu and R. Kauffman},
  journal={Diabetes},
  year={2002},
  volume={51 4},
  pages={
          1083-7
        }
}
A novel nonthiazolidinedione dual peroxisome proliferator- activated receptor (PPAR)-alpha/gamma agonist, LY465608, was designed to address the major metabolic disturbances of type 2 diabetes. LY465608 altered PPAR-responsive genes in liver and fat of db/db mice and dose-dependently lowered plasma glucose in hyperglycemic male Zucker diabetic fatty (ZDF) rats, with an ED(50) for glucose normalization of 3.8 mg small middle dot kg(-1) small middle dot day(-1). Metabolic improvements were… Expand
New therapeutic options for the metabolic syndrome: what's next?
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity*
A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
  • W. Oliver, J. Shenk, +12 authors T. Willson
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2001
Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
Activation of PPARδ alters lipid metabolism in db/db mice
Efficacy of troglitazone on body fat distribution in type 2 diabetes.
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1*
  • Philippe Delerive, Karolien De Bosscher, +7 authors Bart Staels
  • Biology, Medicine
  • The Journal of Biological Chemistry
  • 1999
...
1
2
3
4
...